down arrow

Protara Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74365U1079
USD
5.49
0.12 (2.23%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.365.50

52 Week

2.777.82
Valuation
Technical
Day's Volume

CASH

235.08 k

Shareholding (Mar 2025)

FII

4.14%

Held by 21 FIIs

DII

81.27%

Held by 10 DIIs

Promoter

8.31%

How big is Protara Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Protara Therapeutics, Inc. has a market capitalization of 118.06 million, with net sales of 0.00 million and a net profit of -45.41 million over the latest four quarters. The company reported shareholder's funds of 167.13 million and total assets of 181.45 million as of Dec 24.

Market Cap: As of Jun 18, Protara Therapeutics, Inc. has a market capitalization of 118.06 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Protara Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -45.41 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 167.13 million and total assets of 181.45 million.

Read More

What does Protara Therapeutics, Inc. do?

22-Jun-2025

Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare and specialty diseases. As of March 2025, it has a market cap of $118.06 million and reported a net profit loss of $12 million.

Overview: <BR>Protara Therapeutics, Inc. is a clinical-stage company focused on developing treatments for rare and specialty diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -12 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 118.06 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.78 <BR>Return on Equity: -28.66% <BR>Price to Book: 0.74<BR><BR>Contact Details: <BR>Address: 1 Little West 12Th Street, NEW YORK NY: 10014 <BR>Tel: 1 646 8440337 <BR>Fax: 1 302 6555049 <BR>Website: https://protaratx.com/

Read More

Who are in the management team of Protara Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Protara Therapeutics, Inc. includes Chairman Luke Beshar, CEO Jesse Shefferman, and several directors: Barry Flannelly, Roger Garceau, Richard Levy, Gregory Sargen, and Michael Solomon. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Protara Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Luke Beshar, Chairman of the Board<BR>- Mr. Jesse Shefferman, President, Chief Executive Officer, and Director<BR>- Dr. Barry Flannelly, Director<BR>- Dr. Roger Garceau, Independent Director<BR>- Dr. Richard Levy, Independent Director<BR>- Mr. Gregory Sargen, Independent Director<BR>- Dr. Michael Solomon, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Protara Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Protara Therapeutics, Inc. is in a mildly bearish trend, with daily moving averages and weekly Dow Theory indicating bearishness, despite a mildly bullish MACD; the stock has underperformed the S&P 500 significantly, with a year-to-date return of -39.20% and a five-year decline of -82.49%.

As of 12 September 2025, the technical trend for Protara Therapeutics, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and weekly Dow Theory also showing a mildly bearish signal. While the MACD is mildly bullish on both weekly and monthly time frames, the overall sentiment is tempered by the Bollinger Bands showing a mildly bearish trend on the monthly. <BR><BR>In terms of performance, the stock has underperformed relative to the S&P 500 across multiple periods, with a year-to-date return of -39.20% compared to the S&P's 12.22%, and a significant decline of -82.49% over the past five years against the S&P's 96.61%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 118 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.84

stock-summary
Return on Equity

-35.22%

stock-summary
Price to Book

0.82

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
34.56%
0%
34.56%
6 Months
79.41%
0%
79.41%
1 Year
6.19%
0%
6.19%
2 Years
200.0%
0%
200.0%
3 Years
98.19%
0%
98.19%
4 Years
-20.43%
0%
-20.43%
5 Years
-76.33%
0%
-76.33%

Protara Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-195.05%
EBIT to Interest (avg)
-43.24
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.78
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.81
EV to EBIT
-0.11
EV to EBITDA
-0.11
EV to Capital Employed
0.16
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-145.72%
ROE (Latest)
-28.66%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 7 Schemes (6.27%)

Foreign Institutions

Held by 21 Foreign Institutions (4.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -57.89% vs 15.93% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.50",
          "val2": "-10.60",
          "chgp": "-55.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.00",
          "val2": "-9.50",
          "chgp": "-57.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -10.40% vs 38.79% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-48.80",
          "val2": "-43.30",
          "chgp": "-12.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.60",
          "val2": "-40.40",
          "chgp": "-10.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-16.50
-10.60
-55.66%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-15.00
-9.50
-57.89%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -57.89% vs 15.93% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-48.80
-43.30
-12.70%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-44.60
-40.40
-10.40%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -10.40% vs 38.79% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Protara Therapeutics, Inc. stock-summary
stock-summary
Protara Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. Its product pipeline includes TARA 002 and IV choline chloride for injection. TARA 002 is its lead program focused on the treatment of Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an enzyme replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD).
Company Coordinates stock-summary
Company Details
1 Little West 12Th Street , NEW YORK NY : 10014
stock-summary
Tel: 1 646 84403371 646 8440337
stock-summary
https://protaratx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."